Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients.

Although it did not reach statistical significance due to small sample size, this is consistent with the findings from FASTACT-2 study [ 41 ] and suggests that ctDNA could serve as a predictive biomarker for clinical outcome.

also in 111,027 other papers